



### **III. PROFESSIONAL EXPERIENCE:**

#### **Post-Graduate Education:**

1980-1981	Intern in Medicine, University of Kentucky Department of Medicine
1981-1983	Resident in Medicine, University of Kentucky Department of Medicine
1983-1985	Resident in Urology, University of Kentucky Department of Surgery
1985-1987	Fellowship in Nephrology and Transplantation

#### **Professional Experience:**

1980	University of Kentucky Internship
1981-1983	University of Kentucky Residency (Internal Medicine)
1983-1985	University of Kentucky Residency (Urology)
1985-1987	University of Kentucky Fellowship (Nephrology and Renal Transplantation)

#### **Academic Appointments:**

1987-1994	Assistant Professor of Internal Medicine
1994-2003	Associate Professor of Internal Medicine
2003-present	Professor of Internal Medicine

#### **Clinical Appointments:**

Transplant Nephrologist, UNOS Recognized 1985 – Present
Primary Transplant Physician, UNOS Recognized, Heart, Lung and Heart Lung Transplantation Program, University of Kentucky Medical Center 1992 – Present
Primary Transplant Physician, UNOS Recognized, Pancreas Kidney Transplantation Program 1995 - Present

Staff Nephrologist, University of Kentucky Medical Center  
Staff Nephrologist, Lexington VA Medical Center

Medical Director of Dialysis, University of Kentucky Medical  
Center Hospital 1994 - Present

Medical Director, Kidney Transplantation, University of Kentucky  
Medical Center Hospital 1985 - Present

Medical Director, Kidney-Pancreas Transplantation, University of  
Kentucky Medical Center Hospital 1995 - Present

Medical Director, Lung and Heart/Lung Transplantation,  
University of Kentucky Medical Center Hospital  
1992 - Present

Medical Director, Heart Transplantation, University of Kentucky  
1992-1996, 2002 - Present

Attending Physician, University of Kentucky Medical Center  
1985 – Present

Attending Physician, Veterans Administration Medical Center,  
Lexington, KY 1985 – Present

Director, Organ Failure and Transplantation Network  
2007 - Present

**Consulting Activity:**

Advisory Board, MedImmune, Inc.

Advisory Board, Novartis Pharmaceuticals, Inc.

**Teaching Activity:**

Physical Diagnosis, 1989-1997

Family Practice Review, 1993: Approaching the patient with acute  
renal failure

Family Practice Review, 1994: Proteinuria. when do I worry?

Family Practice Review, 1995: Hematuria. when do I worry?

Surgical Critical Care: CAVH, CAVH/D and SCUF

Family Practice Review, 1996, Obstructive Uropathy and Post-  
Obstructive Diuresis

Pulmonary Critical Care: CAVH, CAVH/D and SCUF  
Renal transplantation

Medical Housestaff (yearly - revolving)

Transplantation Emergencies  
Renal Transplantation  
Evaluation of Hematuria  
Evaluation of Proteinuria  
Renal Stone Disease - Clinical and Metabolic  
Glomerulonephritis  
The Kidney in Systemic Diseases  
Renovascular Hypertension  
Lupus Nephritis  
Systemic Vasculitis  
ANCA-associated Diseases  
Toxic Nephropathy  
Continuous Renal Replacement Therapy  
Infectious Nephropathy  
Obstructive Nephropathy and Post Obstructive Diuresis  
Atheroembolic Renal Failure  
Hereditary and Familial Nephropathies  
Diuretic Use and Resistance  
Acute Renal Failure  
Internal Medicine Board Review: Acute Renal Failure

**Advising Activity:**

1991-Present                      Residents, Internal Medicine  
1993-Present                      Students, Medical School

**Committees:**

Services Committee, Lexington Medical  
Society 1999-2002 and 2005-Present  
Administrative Committee, Lexington Medical Society 2002-2005  
Transplantation Executive Committee 1997-Present  
Intern Selection Committee  
Organ Donation Committee  
Interviewer, Medical Admissions Committee  
Advisory Committee, Kentucky Organ Donor Affiliates  
Financial Aid Committee – Medical Admissions 2002-Present  
Kidney Transplantation Patient Evaluation Committee  
1985-Present  
Heart, Lung, Transplantation Patient Evaluation Committee  
1992-Present

- Special Assignments:** Transplantation Task Force  
The Renal Network, 1995 – 2000 Medical Review Board  
The Renal Network, 2001-2004 Chairman, Transplantation Subcommittee
- Honors:** National Honor Society, 1967  
Quill and Scroll - Honor Society for High School Journalism, 1967  
Rho Chi Society, 1971  
Chief Resident's Award Faculty of the Year  
1992 (Inaugural Award), 1995, 1996  
Chairman's Award for Excellence in Clinical Medicine, 1999
- Professional Activity:** American Society of Nephrology  
  
National Kidney Foundation  
  
American Society of Transplantation  
  
The Transplantation Society  
  
International Society for Heart and Lung Transplantation  
  
Kidney Foundation of Central Kentucky  
  
Renal Network (9 & 10) - Medical Review Board  
International Society of Peritoneoscopies  
  
Kentucky Medical Association  
  
Lexington Medical Society (Services Committee) Chair,  
Secretary-Treasurer Elect  
  
Member, Editorial Board, *Clinical Nephrology*
- Speaking Engagements:** **Regional**  
  
Kidney Transplantation C0-Morbidity Management:  
Cardiovascular, Hypertension, Hyperlipidemia, Obesity, Diabetes  
and Infection.  
National Kidney Foundation of Ohio, Columbus May 2006  
  
New Immunosuppressive Drugs, Renal Physicians Association  
Meeting Regional with Tri-state Renal Network, May 1996
- National**

Invited presentation: CMV Ig in the treatment of cytomegalovirus disease in the transplant patient. ASTP/ASTS, Houston, TX, May 1993 and at:

ICAAC meeting October 18, 1993  
University of Wisconsin, January 1994  
Med. University of South Carolina, March 1994  
ASTP/ASTS, May 1994  
Cedars Sinai, Los Angeles, January 1995  
Loma Linda University, Los Angeles, January 1995  
St. Vincent's Hospital, Los Angeles, January 1995

Invited presentation: T10B9 treatment of  
renal allograft acute rejection:

Emory University College of Medicine October 1994 and Medical  
College of Georgia, October 1994  
Stanford Univ. Medical School, December 1994  
California Pacific Medical Center, December 1994  
UC San Francisco Medical Conference, December 1994  
Cedars Sinai, Los Angeles, January 1995  
Loma Linda University, January 1995  
St. Vincent's Hospital, Los Angeles, January 1995  
Jackson Memorial Hospital, Univ. of Miami, January 1995  
University of Utah, March 1995  
Latter Day Saints Hospital, Salt Lake City, March 1995  
Columbia Presbyterian, May 1995  
Oregon Health Sciences University, September 1995  
University of Arkansas, June 1996  
Associate Editor-Transplantation *Clinical Nephrology*

**Editorial Consultant:**

**Previous Projects:**

Investigator: Determination of efficacy of Ricin A chain MoAb (Zomazyme) in GVHD.

Investigator: Determination of toxicity (phase I study) of *In vivo* T10B9 monoclonal antibody.

Principal Investigator: Investigation of Minnesota antihuman Lymphocyte globulin (MALG) for treatment of acute cellular allograft rejection.

Investigator: Medi 500 induction of immunosuppression in Orthotopic lung transplantation.

Investigator: Renal Network Peritoneal Dialysis Prescription Quality Improvement Project

Investigator: Imtix in Delayed Graft Function

Investigator: Phase II study using T10B9. 1A-31 for reversal of acute renal allograft rejection.

Investigator: Sandimmune Neoral N103 Pharmacokinetic Study

Investigator: In situ modulation of CD3/TCR by T10B9 and OKT3.

Investigator: Acetate-based dialysate solution for control of lactic acidosis in continuous renal replacement therapy.

Investigator: A Phase III, Randomized, Double-blinded placebo controlled multi-center study of the efficacy of Odulimomab (ANTI2FA) in preventing delayed graft function of cadaveric renal allografts in patients not receiving biological induction therapy. Protocol number AFO12396.

Co-Investigator: A Phase II Open-Label study of Medi500 (TIOB9) in the Induction of Immunosuppression for combined kidney and pancreas transplantation.

Co-Investigator: A Phase II, Randomized, Multi-center, Open-label safety study of ISA tx 247 and Cyclosporine (Neoral) in Post-renal Transplant Patients. Protocol number ISA00-16.

Sponsor: Isotechnika Ind.

Funding: \$16,940

Four subjects projected

Open date 10/01, Closed date 09/02

Investigator: Medi 500 induction of immunosuppression in orthotopic heart transplantation.

Co-Investigator: A Phase II Randomized Multicenter, Open-Label Safety Study of ISA tx 247 and Cyclosporine (Neoral®) in Post-Renal Transplant Patients (ISA00-16).

Principal Investigator: A Phase IV, Randomized, Open-label, Comparative, Multi-center study to assess the safety and efficacy of Induction Agents Alemtuzumab

(CAMPATH 1H), Basiliximab (Simulect) or Rabbitt Anti-thymocyte globulin (Thymoglobulin) in combination with Tacrolimus (Prograf), Mycophenolate mofetil (Cellcept) and rapid steroid withdrawal in renal transplant recipients.

Sponsor: Astellas Healthcare

Funding: \$150,000  
Open date January 2005 Closure date February 2006

Principal Investigator: Prograf (tacrolimus) as Secondary Intervention vs. Continuation of Cyclosporin in Patients at Risk for Chronic Renal Allograft Failure. Protocol 20-98-002  
Sponsor: Fugisawa Healthcare  
Funding: \$256,000  
Subjects projected 15 - 32 enrolled  
Open date May 13, 1999, closure date July 2005

### **Current Projects:**

Principal Investigator: A Phase 2, Randomized, Open-Label, Parallel Group, Multi-Center Study to assess the Safety and Efficacy of Alefacept in de novo Kidney Transplant Recipients. (ISN/Protocol 0485-CL-U201)  
Sponsor: Astellas  
Funding: \$156,000  
Subjects Projected: 10  
Open Date: TBD

Principal Investigator: A 4-week multi-center, double-blind, randomized, parallel group study to compare the gastrointestinal safety and tolerability of Myfortic and MMF (cellcept) when administered in combination with calcineurin inhibitors in renal transplant recipients experiencing gastrointestinal intolerance.

(ERL080A)  
Sponsor: Roche  
Funding: \$85,000  
Subjects Projected: 10 enrolled  
Open Date: November 2007, closure date N/A

Principal Investigator: An Open-Label, Prospective, Randomized, Controlled, Multi-center Study Assessing Fixed Dose vs. Concentration Controlled CellCept® Regimens for Patients Following a Single Organ Renal Transplantation in Combination with Full Dose and Reduced Dose Calcineurin Inhibitors (ML17225).

Sponsor: Roche-CTI  
Funding: \$257, 322.20  
Subjects projected: 20 – enrolled 17  
Open date October 2003 Closure date N/A

Principal Investigator: mRNA Profiling for the Diagnosis of Acute Rejection and for the Prediction of Renal Allograft Function (ML18691-A). Sub-study of ML17227

Principal Investigator: Impact of Pharmacogenetics on Mycophenolate Mofetil use (ML19199). Sub study of 17227  
Sponsor: Roche  
Funding: \$7, 279.40  
Open date March 10, 2006 Closure date N/A

Principal Investigator: Open-Label Randomized, Multi-center Study to Evaluate the Efficacy and Safety of Early Calcineurin Inhibitor Withdrawal in Recipients of Primary Renal Allografts Maintained Long-term on Mycophenolate Mofetil: MMF (CellCept®) and Sirolimus (Rapamune).  
Sponsor: Roche CTI  
Funding: \$236, 300  
Subjects projected: 20 – enrolled 16  
Open date November 2003 Closure date N/A

Principal Investigator: Phase III, Randomized, Open-Label, Comparative, Multi-Center Study to Assess the Safety and Efficacy of Prograf (tacrolimus)/MMF, Modified Release (MR) Tacrolimus/MMF and Neoral (cyclosporine)/MMF in De Novo Kidney Transplant Recipients.  
Sponsor: Astellas Healthcare  
Funding: \$292, 890  
Subjects projected: 10 - 8 enrolled  
Open date August 18, 2003 Closure date August 2007

Principal Investigator: Use of Cytomegalovirus Hyperimmune Gammoglobulin in Combination with Plasmapheresis in Highly or Specifically Sensitized Solid Organ Transplant Candidates.  
Sponsor: Medimmune Inc.  
Funding: \$50,000  
Subjects projected 10  
Open date January 2004, closure date none

Principal Investigator: A 4-week multi-center, double blind, randomized parallel group study to compare the gastrointestinal safety and tolerability of Myfortic and MMF (Cell-Cept) when administered in combination with calcineurin inhibitors in renal transplant recipients experiencing gastrointestinal intolerance: MyGain.  
Sponsor: Novartis  
Funding: TBD

Open date July 7, 2006, closure date none

Co-Investigator: A randomized, Open-label study to compare the safety and efficacy of two different serolimus regimens with tacrolimus and mycophenolate mofetil regimen in De Novo allograft recipients.

Sponsor: Wyeth

Funding: \$124, 676

Subjects projected 10

Open date September 2, 2004 closure date N/A

Co-Investigator: Prospective, Randomized, Open-label, Twenty-six Week Study of the Efficacy and Safety of Converting Kidney and Liver Transplant Recipients with tacrolimus-Associated Abnormal Glucose Metabolism to Neoral with C2 Monitoring.

Sponsor: Novartis

Co-Investigator: Randomized, Open-Label, Comparative Evaluation of Conversion from Calcineurin Inhibitors to Sirolimus versus Continued Use of Calcineurin Inhibitors in Renal Allograft Recipients. Protocol 0468H1-316-US.

Sponsor: Wyeth

Funding: \$430, 380

Subjects projected 20

Open date April 1, 2004 Closure N/A

Co-Investigator: Follow-up to the Multicenter Phase II Comparative Trial of Thymoglobulin versus Simulect for the Prevention of Delayed Graft Function and Acute Allograft Rejection in Renal Allograft Recipients.

Sponsor: Sungstat Medical Corp.

Funding: \$105, 533

Subjects projected 20 – enrolled 5

Open date May 20, 2002 Closure September 2004

Co-Investigator: Prospective, Randomized, Multicenter, Double-Blind Study of Early Corticosteroid Cessation vs. Long-Term Maintenance Corticosteroid Therapy with Prograf and CellCept in Primary Renal Transplant Recipients.

Sponsor: Fugisawa Healthcare

Funding: \$120,000

Subjects projected: 20 patients

Open date August 2001, Closure November 2006

Co-Investigator: A Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Study of an Anti-T-Lymphocyte Immunoglobulin

(EZ-2053) in the Prophylaxis of Acute Pulmonary Allograft Rejection in Adult Recipients of Primary Pulmonary Allograft(s).  
Sponsor: Enzon Pharmaceuticals, 2004  
Funding: \$127, 553  
Subjects projected: 10  
Open date March 22, 2005    Closure pending

Co-Investigator: Belatacept evaluation of nephroprotection and efficacy as first-time immunosuppression trial-extended criteria donors (BENEFIT-EXT) (Protocol IM103027)  
Sponsor: Bristol Meyer Squibb  
Funding: \$212, 009  
Subjects projected: 6  
Open date April 2006 Closure pending

Co-Investigator: A 24 month, multi-center, randomized, open-label non-inferiority study of efficacy and renal function comparing concentration controlled Certican in two doses (1.5 mg/day and 3 mg/day) with reduced Neoral versus 1.44 gram Myfortic with standard dose Neoral in De Novo renal transplant recipients (Novartis Crad001A2309)  
Sponsor: Novartis  
Funding: \$93, 215  
Subjects projected: 8  
Start date January 2006 Closure pending

Co-investigator: A Phase IIB randomized multi-center open-label concentration-controlled safety study of ISA247 and tacrolimus (Prograf) in De Novo renal transplant patients. Protocol ISA05-01  
Sponsor: Isotechnica, Inc.  
Funding: \$80, 287  
Open date November 23, 2006 Closure N/A

## **Research and Creative Productivity:**

### Publications:

1. Miller, R.E., WAID, T.H., Joyce, M.P.: Direct neural inhibition of insulin secretion in response to systemic hypoglycemia. *Am. J. Phys.*, 230:1090-1094, 1976.
2. Gomella, L.G., WAID, T.H., Petrou, S.P., Flanigan, R.C., McRoberts, J.W.: Renal vein thrombosis presenting as renal mass. *Urology*. 35:164-167, 1989.

3. WAID, T.H., Lucas, B.A., Amlot, P., Janossy, G., Cammisuli, S., Brown, S., Thompson, J.S. T10B9.1A-31 anti T-cell monoclonal antibody: Preclinical studies and clinical treatment of solid organ allograft rejection. *Am. J. Kid. Dis.* 14:61-70, 1989.
4. WAID, T.H., Lucas, B.A., Amlot, P., Brown, S., Janossy, G., Thompson, J.S. Treatment of acute cellular allograft rejection with T10B9.1A-31 anti T cell monoclonal antibody. *Transplantation Proc* 21:1778-1784, 1989.
5. WAID, T.H., Lucas, B.A., Thompson, J.S., Munch, L.C., Brown, S., Kryscio, R., Prebeck, R., VanHoy, M.A., Jezek, D.: Treatment of acute rejection with anti T-cell antigen receptor complex  $\hat{A}\beta$  (T10B9.1A-31) or anti CD3 (OKT3) monoclonal antibody: Results of a prospective randomized double blind trial. *Transplantation Proc* 23(No. 1):1062-1065, 1991.
6. WAID, T.H., Lucas, B.A., Thompson, J.S., Brown, S., Munch, L., Prebeck, R., Jezek, D.: Treatment of acute cellular rejection with T10B9.1A-31 or OKT3 in renal allograft recipients. *Transplantation*, 53(No. 1):80-86, 1992.
7. Pierce, S.T., Doukas, M.A., WAID, T.H.: Immunosuppression in renal transplantation does not increase the incidence of native renal cancer. *International J. Oncol.* 2:1059-1062, 1993.
8. Lucas, B.A., WAID, T.H., Thompson, J.S., Brown, S., Munch, L.C., Kryscio, R., Prebeck, R.: Comparison of T10B9.1A-31 and OKT3 in treating acute renal allograft rejection. *Transplantation Proc.* 25(No.1):543, 1993
9. WAID, T.H.: Successful prevention of cytomegalovirus disease with cytomegalovirus immune globulin. *Pharmacy and Therapeutics* 19:760-774, 1994.
10. WAID, T.H., McKeown, J.W.: Cytomegalovirus hyperimmune globulin for CMV disease refractory to ganciclovir in renal transplantation. *Transplantation Proc.* 27(No.5):46, 1995.
11. Barone G, Bunke CM, Choc GM, Hricik DE, Jin JH, Klein JB, Marsh CL, Min DI, Pescovitz MD, Pollak R, Pruett TL, Stinson JB, Thompson JS, Vasquez E, Waid T, Wombolt DG, Wong RL. Safety and tolerability of Neoral™ versus Sandimmune®: a randomized, double-blind comparison in primary renal allograft recipients. *Transplantation*, 61:968-987, 1996.
12. Barone G, Choc GM, Hricik DE, Jim J, Klein JB, Min DI, Pescovitz MD, Pollak R, Pruett TL, Stinson JB, Thompson JS, Vasquez E, WAID T, Wombolt DG, Wong RL. Safety and tolerability of Neoral® vs. Sandimmune®: 1-year data in primary renal allograft recipients. In press, *Transplantation Proc*, 1996
13. Barone G, Chang CT, Choc GM, Klein JB, Marsh CL, Meligengi JA, Min DI, Pescovitz MD, Pollak R, Pruett TL, Stinson JB, Thompson JS, WAID T, Wombolt DG, Wong RL. The pharmacokinetics of a microemulsion formulation of cyclosporine Neoral™ in primary renal allograft recipients. *Transplantation* 61:875-880, 1996.

14. Brown, Stephen A., Lucas, Bruce A., WAID, Thomas H., McKeown, J. Wade, Barve Shirish, Jackson, Lisa R., Thompson, John S. T10B9 (MEDI-500) Mediated Immunosuppression: Studies on the Mechanism of Action. Accepted for publication in *Clinical Transplantation*, December 1996.
15. Pescovitz MD, Barone G, Choc MG Jr, Hricik DE, Swang D-S, Jin JH, Klein JB, Marsh cL, Min DI, Pollak R, Pruett TL, Stinson JB, Thompson JS, Vasquez E, WAID T, Wombolt DG, Wong RL: Safety and tolerability of cyclosporine microemulsion vs. cyclosporine: 2-year data in primary renal allograft recipients. *Transplantation* 63(5):778-780, 1997.
16. WAID, T.H., Lucas B.A., Thompson, J.S., McKeown, J.W., Brown, S., Jackson, L. Treatment of renal allograft rejection with T10B9-1A-31 or OKT3: Final analysis of a phase II clinical trial. *Transplantation*, 64(2),1997.
17. Bruce, R.G., WAID, T.H., Lucas, B.A. Understanding postobstructive diuresis. *Contemporary Urology* 9(6):53, 1997.
18. WAID, T.H., Thompson, J.S., McKeown, J.W., Brown, S.A., Sekela, M.E.. Induction immunotherapy in heart transplantation with T10B9.1A-31: a phase I study. *J Heart Lung Transp.* 16:913-916, 1997.
19. WAID, T.H. Update: kidney transplant rejection and treatment.. *Mediguide to Nephrology*, New York, DellaCorte, Vol. 5, Issue 4, 1997.
20. Brown, S., Lucas, B., WAID, T.H., McKeown, W. John, Tsuchida, M., Thompson, J. T10B9 Action: The effect of anti-T-cell antibody mitogenicity and graft rejection on the first dose cytokine response. *Transplantation Proc*, Vol 29: 315-316, 1997.
21. WAID, T.H. Urinary tract obstruction and postobstructive diuresis. *Mediguide to Nephrology*, New York, DellaCorte, Vol. 6, Issue 2, 1998.\*
22. Marsh, C.L., Pescovitz, M.D., Wong, R.L., Barone, G., Choc, M.G. Jr., Hwang, D.S., Klein, J.B., Min, D.I., Pollak, R. Pruett, T.L., Stinson, J.B., Thompson, J.S., Vasquez, E., Waid, T., Wombolt, D.G., Chang, C.T. Abbreviated pharmacokinetic profiles in area-under-the-curve monitoring of cyclosporine therapy in de novo renal transplant patients treated with Sandimmune® or Neoral®. *Therapeutic Drug Monitoring.* 21:27-34, 1999.\*
23. Reddy, K.S., Stablein, D., Taranto, S., Stratta, R.J., Johnston, T.D., WAID, T.H., McKeown, J.W., Lucas, B.A., Ranjan, D. Long-Term survival following simultaneous kidney-pancreas transplantation versus kidney transplantation alone in patients with type 1 diabetes mellitus and renal failure. *Transplantation Proc*, 33, 1659-1660, 2001.
24. Reddy, K.S., Ranjan, D., Johnston, T.D., Kahn, T., Karounes, D., WAID, T.H., McKeown, J.W., Lucas, B.A., and Mentzer, R., Pancreas Transplantation: Current Status and Experience at the University of Kentucky. *JKMA* 100: 274-280, 2002.

25. Tim Ruff, M.D., K. Sudhakar Reddy, M.D., Thomas D. Johnston, M.D., Thomas WAID, M.D., Wade McKeown, M.D., Taqi Kahn, M.D., Dinesh Ranjan, M.D., Bruce Lucas, M.D., Transplantation of pediatric en bloc cadaver kidneys into adult recipient: A Single-Center Experience. *Am Surg* 68: 1-3, 2002.
26. Reddy K.S., Stablein D., Taranto S., Stratta R.J., Johnston T.D., WAID T.H., McKeown J.W., Lucas B.A., Ranjan D. Long-term survival following simultaneous kidney-pancreas transplantation versus kidney transplantation alone in patients with type 1 diabetes mellitus and renal failure. *Am J Kidney Dis* 41(2):464-70, 2003.
27. Romero A.L., Reddy K.S., Johnston T.D., WAID T.W., McKeown J.W., Lucas B.A., Ranjan D. Simultaneous kidney-pancreas transplantation in a patient with small lymphocytic lymphoma. *Transplantation* 75(3):414-6, 2003.
28. Reddy, K.S., Davies, D., Ormond, D., Tuteja, S., Lucas, B.A., Johnston, T.D., WAID, T.H., McKeown, J.W., and Ranjan, D. Impact of acute rejection episodes on long-term graft survival following simultaneous kidney-pancreas transplantation. *Am. J. Transplantation* 3(4):439-44, 2003.
29. Reddy K.S., Mastrangelo M.D., Johnston T. Khan T., WAID T., McKeown W., Lucas B., Ranjan D. Recipient outcome following living donor kidney transplantation using kidneys procured laparoscopically. *Clin Transplant* 17 Suppl 9:44-7, 2003.
30. Flynn J.D., Akers W.S., Jones M., Sterkovic N., WAID T.H., Mullett T., Jahania M.S. Treatment of Respiratory Syncytial Virus Pneumonia in a Lung Transplant Recipient: Case Report and Review of the Literature. *Pharmacotherapy* 24:932-938, July 2004.
31. WAID T.H. for the CRAF Study Group. Tacrolimus as Secondary Intervention Versus Cyclosporine Continuation in Patients at Risk for Chronic Renal Allograft Failure. *Clinical Transplantation*, 19: 573-580, Oct 2005.
32. Taylor L. M., Smith K. M., Lewis D. A., Waid T. H., Clifford T.M., Timing of Renin-Angiotensin System Blockade in Renal Transplantation. Submitted to *Clinical Nephrology*, 2005.
33. Shihab F. S., Waid T., Conti D., Yang H., Holman M., Mulloy L., Henning A. K., Holman J. Jr., First M. R. for the CRAF Study Group. Conversion from Cyclosporine to Tacrolimus in Patients at Risk for Chronic Renal Allograft Failure: 60-month Results of the CRAF Study. *Transplantation*, 85: 1261-1269, May 2008.
34. Waid, TH; Thompson, JS; Siemionow, M; and Brown, SA: T10B9 Monoclonal Antibody: A short-acting non-stimulating monoclonal antibody that spares gamma/delta T-cells and treats and prevents cellular rejection. Submitted to *Drug Design Development and Therapy*, 2008.

### Books and Book Chapters

1. WAID, T.H.: Transplantation immunobiology and immunopharmacology. In: *Urologic Surgery*. Glenn, J. (ed), 4th edition, Lippincot, Philadelphia, PA, 1989.
2. WAID, T.H.: Prevention and treatment of renal allograft rejection. In *Current Therapy in Nephrology and Hypertension*. Glassock, R. (ed) 3rd edition, Mosby, St. Louis, MO, 1998.
3. Waid, T.H. Urinary tract obstruction. In *Clinical Nephrology, Dialysis and Transplantation*. Malluche, H.H. (ed) 1st edition, Dustri-Verlag, Munich, Germany, 1999.
4. Waid, T.H. Antirejection therapy: alternative modalities. In *Textbook of Nephrology*, Glassock and Massry (eds.), Williams and Wilkins, Baltimore, MD, 2001.
5. Waid, T.H. Evaluating solid and cystic lesions of the kidney. In *Clinical Nephrology, Dialysis and Transplantation*, Malluche, H.H., Sawaya, B.P., Hakim, R.M., Sayegh, M.H. (eds.), Dustri-Verlag, Munich, Germany, 1999.

### Monographs

1. WAID, T.H.: T10B9.1A-31 IgMk anti-T cell receptor  $\alpha\beta$  murine monoclonal antibody. *Drugs of the Future* 19(2):131-133, 1994.
2. Thompson JS, Brown SA, Hensley-Downey PI, Lucas BA, WAID TH, McKeown JW: T10B9.1A-31 anti-human  $\alpha/\beta$  T-cell receptor antibody. Recent developments in transplantation medicine. Glenview, IL, Physicians and Scientists Publishing Co., 1995.

### Abstracts

1. WAID, T.H., Joyce, M.P. and Miller, R.E.: Neurally mediated alternation of insulin secretion by indigenous stimuli. Presented at the Annual Meeting of the American Diabetes Association, June, 1976, *Diabetes* 24, 52:403, 1976.
2. Byers, V., Kernan, N., Henslee, J., Gingrich, R., Frame, J., WAID, T.H., Messino, M., Schak, R.M., O'Reilly, R., Thompson, J., Dupont, B., Scannon, P.: A phase I study using pan T lymphocyte - ricin A chain immunotoxin to treat graft versus host disease. Submitted to American Association for Cancer Research, 1987.
3. WAID, T.H., Lucas, B.A., Amlot, P., Brown, S., Janossy, G., Thompson, J.S.: Treatment of renal allograft rejection with T10B9, a new anti-T cell monoclonal antibody. Presented at the American Society of Transplant Physicians, Chicago, 1988 and the 12th International Congress of Transplantation, Sydney, Australia, 1988.

4. WAID, T.H., Lucas, B.A.: Cyclosporine minimizes re-rejection in OKT3 treated, azathioprine-prednisone maintained prospectively HLA matched renal allografts. Presented at the American Society of Transplant Physicians, 1988.
5. Lucas, B.A., Munch, L.A., WAID, T.H., McRoberts, J.W., Flanigan, R.C.: Pull-through ureterostomy to isolated ileal stoma. Presented at the Meeting of the American Urological Association, Inc., 1990.
6. WAID, T.H., Lucas, B.A., Thompson, J.S., Munch, L.C., Brown, S., Kryscio, R., Prebeck, R., VanHoy, M.A., Jezek, D.: Treatment of acute rejection with anti T-cell antigen receptor complex  $\hat{A}\beta$  (T10B9.1A-31) or anti CD3 (OKT3) monoclonal antibody: Results of a prospective randomized double blind trial. Presented at the 13th International Congress of the Transplantation Society, San Francisco, CA, August 21, 1990.
7. WAID, T.H., Lucas, B.A., Thompson, J.S., Brown, S., Munch, L., Prebeck, R., Jezek, D.: Treatment of acute cellular rejection with T10B9.1A-31 or OKT3 in renal allograft recipients. Presented at the American Society of Transplant Physicians 10th Annual Meeting, Chicago, IL, 1991.
8. Brown, S., Jezek, D., Prebeck, R., Lucas, B., WAID, T., Thompson, J.: Reversal of acute renal allograft rejection by the non-mitogenic IgM anti T-cell monoclonal antibody T10B9. Submitted to Federation of American Societies of Experimental Biology, 1991.
9. Munch, L.C., Lucas, B.A., WAID, T.H., Thompson, J.S.: Prospective DR matching for cadaveric renal transplants: Long-term follow-up from a single center. Presented at the American Society of Transplant Physicians, 1991.
10. Ryo, U.Y., Greenwell, M., Munch, L.C., Simmons, G., WAID, T., Lucas, B.A.: Difference between Tc-99m-MAG3 and Tc-99m-DTPA in demonstrating early changes of renal tubular cell function on excretion/filtration time-activity curves. Presented at the Society of Nuclear Medicine 39th Annual Meeting, Los Angeles, CA, 1992.
11. Ryo, U.Y., Munch, L.C., Greenwell, M., Simmons, G., WAID, T., Lucas, B.A.: Comparison of Tc-99m-DTPA and Tc-99m-MAG3 as dynamic imaging agents for evaluation of renal allograft. Presented at The Society of Nuclear Medicine 39th Annual Meeting, Los Angeles, CA, 1992.
12. WAID, T.H., Lucas, B.A., Thompson, J.S., Mitchell, B., Munch, L.C., Prebeck, R., Oberly, E.: In situ modulation may predict successful treatment of acute cellular rejection with T10B9.1A-31 but not necessarily with OKT3. Presented at the American Society of Transplant Physicians 11th Annual Scientific Meeting, Chicago, IL, 1992.
13. Lucas, B.A., WAID, T.H., Thompson, J.S., Brown, S., Munch, L.C., Kryscio, R., Prebeck, R.: Comparison of T10B9.1A-31 and OKT3 in treating acute renal allograft rejection. Presented at the 14th International Congress of Transplantation, Paris, France, 1992.

14. WAID, T.H., Lucas, B.A., Thompson, J.S., Mitchell, B., Munch, L.C., Prebeck, R., Oberly, E.: Modulation of CD3 *in situ* may be necessary for successful treatment of acute rejection with T10B9.1A-31 but not with OKT3. *JASN* 3(3):886, 1992.
15. WAID, T.H., Lucas, B.A., Thompson, J.S., Brown, S., Munch, L.C., Kryscio, R. Prebeck, R.: Treatment of acute rejection in renal allografts with T10B9.1A-31 or OKT3 monoclonal antibody. *JASN* 3(3):886, 1992.
16. Ryo, U.Y., Munch, L.C., Greenwell, M., Simmons, G.H., WAID, T.H.: Sensitivity of renal allograft scintigraphy with Tc-99m MAG<sub>3</sub> compared with that with TC-99m DTPA detection of early acute tubular necrosis or drug toxicity reactions. *Radiology* 185(p): 212, 1992.
17. Sekela, M.E., WAID, T.H., McKeown, J.W., Burki, N.K.: Single lung transplantation at the University of Kentucky. 38th Annual Kentucky Thoracic Society Scientific conference on Pulmonary Disease, March 1993.
18. Brown, S.A., Jezek, D.A., Prebeck, R.J., Lucas, B.A., WAID, T.H., Thompson, J.S.: Mechanisms of improved anti-rejection therapy using the anti T cell monoclonal antibody T10B9. 16th Annual Meeting American Society for Histocompatibility and Immunogenetics, November 1990.
19. Brown, S., Prebeck, R., Rhoades, J., Lucas, B., Munch, L., WAID, T., Thompson, J.: Effective reversal of human acute cellular renal allograft rejection with retention of gamma/delta TGR expression during monoclonal antibody therapy. Annual Meeting AAI/CIS, 1993.
20. WAID, T.H., McKeown, J.W.: Treatment of cytomegalovirus disease with CMV Ig through renal transplantation patients. *JASN* 4:966, 1993.
21. Sekela, M.E., WAID, T.H., McKeown, J.W., Burki, N.K.: Single lung transplantation at the University of Kentucky. Presented at the annual meeting of the Kentucky Thoracic Society, Louisville, KY 1993.
22. Sekela, M.E., Taylor, C., WAID, T.H., McKeown, J.W., Berger, R., Burki, N. Single lung transplantation in Kentucky. Presented at the annual meeting of the Kentucky Thoracic Society, Louisville, KY 1994.
23. WAID, T.H., Lucas, B.A., Thompson, J.S., McKeown, J.W., Brown, S.: Treatment of renal allograft rejection with T10B9.1A-31 or OKT3: final analysis of a phase II clinical trial. Presented at the American Society of Transplant Physicians 13th Annual Meeting, Chicago, IL, May 1994.
24. Brown, S., Lucas, B., WAID, T., McKeown, W.: Human cytokine release following the first dose of either OKT3 or T10B9.1A31 in an *in vivo* SCID-human mouse model system. Presented at the American Society of Transplant Physicians Annual Meeting, Chicago, IL 1994.

25. WAID, T., Lucas, B.A., Thompson, J.S., McKeown, J.W., Brown, S.A.: T10B9.1A-31 effectively reverses renal allograft rejection crisis with fewer side effects, less cytokine release and no severe infections. *JASN* 5:1042, 1994.
26. WAID, T., Lucas, B.A., Thompson, J.S., McKeown, J.W., Brown, S.A.: Improved graft and patient survival with T10B9.1A-31 or OKT3 monoclonal antibody for treatment for primary rejection. *JASN* 5:1042, 1994.
27. Brown, S.A., Thompson, J.S., Lucas, B., Sekela, M., WAID, T., McKeown, W.: IL-10 induction by T10B9.1A31 or OKT3 anti-T cell therapy in kidney and heart transplant recipients. *JASN* 5:827, 1994.
28. WAID, T.H., Sekela, M.E., Thompson, J.S., McKeown, J.W., Jackson, L.R.: Induction therapy with T10B9.1A31 is equivalent to OKT3 in cardiac allograft recipients. Presented at the International Society for Heart and Lung Transplantation 15th Anniversary Meeting, April 1995.
29. Sekela, M.E., Burki, N.K., Berger, R., WAID, T.H., McKeown, J.W.: Liberalizing donor criteria for single lung transplant. Presented at the International Society of Heart Lung Transplantation annual conference, 1995.
30. Sekela, M.E., Burki, N.K., Berger, R., McKeown, J.W., WAID, T.H.: University of Kentucky lung transplantation: a recipient limited program. Presented at the Kentucky Thoracic Society annual meeting, 1995.
31. WAID, T.H., Thompson, J.S., Lucas, B.A., McKeown, J.W.: Severe infection occurs less frequently in renal allograft recipients treated for rejection with T10B9.1A-31 than in OKT3-treated patients. Presented at the First Annual Symposium on Controversies in Transplant Infection, Tucson, AZ, February 1995.
32. WAID, T.H., Sekela, M.E., McKeown, J.W., Taylor, C., Little, S., Cytolytic induction therapy does not increase the risk of cytomegalovirus disease in lung transplantation recipients treated with Cytogam and acyclovir. Presented at the First Annual Symposium on Controversies in Transplant Infection, Tucson, AZ, February 1995.
33. WAID, T.H., McKeown, J.W. CMV Ig successfully treats cytomegalovirus disease refractory to ganciclovir in renal transplant patients. Presented at the First Annual Symposium on Controversies in Transplant Infection, Tucson, AZ, February 1995.
34. Costa, M., Sawaya, P., WAID., T.H.: Is a single functioning kidney a contraindication for percutaneous needle biopsy? Presented at the National Kidney Foundation Spring Clinical Nephrology Meetings, March, 1995.
35. WAID, T.H., Thompson, J.S., Lucas, B.A., McKeown, J.W.: Severe infection occurs less frequently in renal allograft recipients treated for rejection with T10B9.1A-31 than in OKT3-treated patients. *JASN* 6:(3):1120, 1995.

36. WAID, T.H., Thompson, J.S.: Modulation of CD 3 in situ occurs with T10B9.1A-31 and OKT3 treatment for acute rejection and may be necessary for successful treatment with T10B9.1A-3 or OKT3. *JASN* 6:(3):1066, 1995.
37. Marsh, C.L., Pruett, T.L., Min, D.I., Thompson, J.S., WAID, T., Bunke, C.M., Klein, J.B., Pescovitz, M.D., Pollak, R., Vasquez, E., Barone, G., Wombolt, D.G., Stinson, J.B., Wong, R.L., Choc, M.G. Jr., Hwang, D.S., Chang, C.T. Abbreviated pharmacokinetic (PK) profiles in area-under-the-curve (AUC) monitoring of cyclosporine (CsA) therapy in de novo renal transplant patients. *JASN* 6(3):1103, 1995.
38. Pescovitz M, Wombolt D, Pruett T, Stinson J, Min D, Thompson J, Waid T, Klein J, Pollak R, Vasquez E, Barone G, Hricik D, Choc M, Jin J, Wong R: Comparison on one year safety in de novo renal transplant patients treated with Sandimmune® or Neoral®. *Cybercongress: Transplantation in the Next Millenium - Advances in Technology and Immunosuppression*. November 13-15, 1995, p. 31.
39. WAID TH, Byrd SG: Successful control of lactic acidosis in ten patients using acetate-based dialysate for continuous renal replacement therapy. Presented at the Second International Conference on Continuous Renal Replacement Therapy, San Diego, CA, Feb. 10, 1997.
40. Pollak R, Vasquez E, Pruett TL, Pescovitz MD, Wombolt D, Barone G, Bunke C, Klein JB, Thompson JS, WAID T, Marsh cL, Min DI, Stinson JB, Choc MG, Wong RL, Chang CT. Cyclosporine bioavailability of Neoral and Sandimmune in white and black de novo renal transplant recipients. Presented at the American Society of Transplant Physicians annual meeting, May 1997.
41. WAID T, Winstead PS. Continuous renal replacement therapy (RRT) in patients with lactic acidosis: successful control of lactate levels with acetate-based dialysate. *XVth International Congress of Nephrology, XIth Latinamerican Congress of Nephrology*, Buenos Aires, 1999.
42. Reddy KS, Johnston T, Thacker L, WAID T, McKeown J, Thompson J, Lucas B, Ranjan D. Analysis of causes of graft failure after cadaveric kidney transplantation compared to living unrelated donor kidney transplantation. Submitted to *The American Society of Transplant Surgeons*, 1999.
43. Reddy KS, Thacker L, Johnston T, WAID T, McKeown J, Thompson J, Lucas B, Ranjan D. Is cadaver donor a risk factor for acute rejection? Submitted to *The American Society of Transplant Surgeons*, 1999.
44. WAID T, Winstead PS: Control of lactic acidosis with continuous renal replacement therapy (RRT) using acetate-based dialysate. Presented to the *American Society of Nephrology annual meeting*, 1999.
45. Reddy KS, Davies D, Ormond D, Johnston TD, WAID TH, McKeown JW, Lucas BA, Ranjan D: Impact of Acute Rejection Episodes on the Long-Term Graft Survival in Kidney-Pancreas

Transplant Recipients. Submitted to the 8<sup>th</sup> Congress International Pancreas and Islet Transplant Association, Innsbruck, June 12-15, 2001.

46. Johnston TD, Reddy KS, WAID TH, McKeown JW, Lucas BA, Thompson JS, Ranjan D: Prevention of Acute Rejection in Pancreas Transplant Recipients Using T10B9: A Pilot Study. Submitted to the 8<sup>th</sup> Congress International Pancreas and Islet Transplant Association, Innsbruck, Austria, June 12-15, 2001.
47. WAID TH, Holman M, and Mulloy L: Prograf as a secondary intervention in chronic renal allograft failure; one year data: Presented to the 2<sup>nd</sup> International Congress of Immunosuppression, San Diego, CA, December 5, 2001.
48. WAID TH, Holman M, Mulloy L, et. al: Prograf as a secondary intervention in chronic renal allograft failure; two year data: Presented to the 14<sup>th</sup> International Congress of the Transplantation Society, Miami Beach, FL, September 29, 2002.
49. WAID TH; Prograf as a secondary intervention in chronic renal allograft failure; three year data; Presented to the American Transplant Congress, Washington, DC, June 10, 2003.
50. Taylor, LM, Smith KM, Lewis DA, Clifford TM, Timing of Renin-Angiotensin System Blockade in Renal Transplantation. Presented American College of Clinical Pharmacology, San Francisco, CA, August 2005
51. Shihab F, Waid TH, Conti T, Yang IT, Holman M, Mulloy L, Henning A, Westerkamp J, Holman J, First MR, The CRAF Study Group. Tacrolimus (TAL) as a secondary intervention vs Cyclosporine (CSA) continuation in patients at risk for chronic allograft failure: 60 month results. Presented to the World Transplant Congress. Boston, MA July 26, 2006.
52. Scandling J, Mulguon Kar S, Shidban H, Waid T, Peddi VR, Patel D. Effective Conversion from a Calcineurin Inhibitor (CNI) Based Regimen to Sirolimus on Proteinuria: 1-Year results of the Spare – the – Nephron Trial in Renal Transplant Recipients. Presented at the American Society of Nephrology Meeting, San Francisco, CA, November 2007.
53. Waid, TH; Thompson, JS; Siemionow, M; and Brown, SA: T10B9 Monoclonal Antibody: A short-acting non-stimulating monoclonal antibody that spares gamma/delta T-cells and treats and prevents cellular rejection. Presented at the 17<sup>th</sup> International Congress of the Transplantation Society, Sydney Australia, August 2008.